Amino Acid Nutrition in the Critically-ill

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

January 28, 2026

Study Completion Date

February 28, 2026

Conditions
Critical IllnessInflammationMalnutrition
Interventions
DIETARY_SUPPLEMENT

Peptamen 1.5% via enteral

Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.

DIETARY_SUPPLEMENT

Prosol 20% IV to 1.75g/kg/day

Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.

DIETARY_SUPPLEMENT

Prosol 20% IV to 2.5g/kg/day

Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.

Trial Locations (1)

H4A 3J1

McGill University health Centre, Montreal

All Listed Sponsors
lead

Arnold Kristof

OTHER

NCT02865408 - Amino Acid Nutrition in the Critically-ill | Biotech Hunter | Biotech Hunter